C. Oldenhuis

发表

A phase Ib study of the VEGF receptor tyrosine kinase inhibitor tivozanib and modified FOLFOX-6 in patients with advanced gastrointestinal malignancies.

M. Cotreau, E. D. de Vries, A. Strahs, 2015, Clinical colorectal cancer.

Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors

Jeffrey W. Scott, Sunil Sharma, H. Burris, 2014, Investigational New Drugs.

Translating TRAIL-receptor targeting agents to the clinic.

E. D. de Vries, S. de Jong, J. Gietema, 2013, Cancer letters.

Phase I trial of LBY135, a monoclonal antibody agonist to DR5, alone and in combination with capecitabine in advanced solid tumors

de Elisabeth G. E. Vries, Jeffrey W. Scott, H. Burris, 2008 .

Sulindac Inhibits β-Catenin Expression in Normal-Appearing Colon of Hereditary Nonpolyposis Colorectal Cancer and Familial Adenomatous Polyposis Patients

H. Hollema, J. Keller, T. van der Sluis, 2005, Cancer Epidemiology Biomarkers & Prevention.

Targeting TRAIL towards the clinic.

E. D. de Vries, S. de Jong, F. Giles, 2011, Current drug targets.

Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study

V. Velculescu, G. Meijer, R. Brosens, 2020, BMC Cancer.

Effect of physical exercise on the hippocampus and global grey matter volume in breast cancer patients: A randomized controlled trial (PAM study)

M. D. de Ruiter, R. Mandl, D. Sommeijer, 2022, NeuroImage: Clinical.

Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study

S. Sleijfer, E. D. de Vries, J. Verweij, 2009, Clinical Cancer Research.

Effect of physical exercise on cognitive function after chemotherapy in patients with breast cancer: a randomized controlled trial (PAM study)

M. D. de Ruiter, D. Sommeijer, A. May, 2022, Breast Cancer Research.

Prognostic versus predictive value of biomarkers in oncology.

E. D. de Vries, J. Gietema, S. Oosting, 2008, European journal of cancer.

Correction: Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: A Phase I Study

J. Verweij, C. Mom, C. Oldenhuis, 2009, Clinical Cancer Research.

Targeting TRAIL death receptors.

E. D. de Vries, S. de Jong, A. Walenkamp, 2008, Current opinion in pharmacology.

Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study

S. Sleijfer, E. D. de Vries, J. Verweij, 2009, Clinical Cancer Research.

A phase Ib, open-label, dose-escalation study of tivozanib and FOLFOX6 in patients (pts) with advanced gastrointestinal (GI) tumors.

M. Cotreau, E. D. de Vries, J. Gietema, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.